Stephen Liu
MD
Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics
Georgetown Lombardi Comprehensive Cancer Center
May 27, 2025
Episode
292
Soundcloud
Share
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recent FDA approval of telisotuzumab vedotin, an antibody-drug conjugate, for NSCLC with high c-MET expression. Dr. Mor Moskovitz and Dr. Jonathan Goldman joined the conversation to help review the data and offer perspective on this new agent.
Guest
Jonathan Goldman
MD
Professor of Medicine, Director of Clinical Trials in Thoracic Oncology & Associate Director of Drug Development
UCLA Hematology & Oncology
Mor Moskovitz
MD
Head of Thoracic Oncology Service
Davidoff Cancer Center
Beilinson Medical Center
